<DOC>
	<DOCNO>NCT01605227</DOCNO>
	<brief_summary>This study evaluate effect cabozantinib compare prednisone overall survival men previously treat metastatic castration-resistant prostate cancer bone-dominant disease experience disease progression docetaxel-containing chemotherapy abiraterone MDV3100 .</brief_summary>
	<brief_title>Study Cabozantinib ( XL184 ) Versus Prednisone Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel Abiraterone MDV3100</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Histological cytological diagnosis castration resistant prostate cancer ( serum testosterone less 50 ng/dL ) . Evidence bone metastasis related prostate cancer bone scan . Received prior docetaxel ( minimum cumulative dose 225 mg/m2 ) either abiraterone MDV3100 treatment evidence prostate cancer progression agent independently . Maintenance LHRH agonist antagonist unless treat orchiectomy . Recovered toxicity relate prior treatment , unless toxicity clinically non significant easily manageable . Adequate organ marrow function . Capable understand comply protocol requirement sign informed consent form . Sexually active fertile patient partner must agree use medically accept method contraception ( eg , barrier method , include male condom , female condom , diaphragm spermicidal gel ) course study 4 month last dose study treatment . Prior treatment cabozantinib . Treatment docetaxel , abiraterone , MDV3100 last 2 week ; type cytotoxic investigational anticancer agent last 2 week . Radiation within 4 week ( exclude mediastinum ) radionuclide treatment within 6 week randomization . Known brain metastasis cranial epidural disease . Requires concomitant treatment , therapeutic dos , anticoagulant . Requires chronic concomitant treatment strong CYP3A4 inducer ( eg , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. John 's Wort ) . Uncontrolled , significant intercurrent illness include , limited , cardiovascular disorder , gastrointestinal disorder , active infection , nonhealing wound , recent surgery . Clinically significant hematemesis hemoptysis , sign indicative pulmonary hemorrhage last 3 month , history significant bleeding past 6 month . Cavitating pulmonary lesion ( ) lesion invade encase major blood vessel . QTcF &gt; 500 m within 7 day randomization . Unable swallow capsule tablet . Previouslyidentified allergy hypersensitivity component study treatment formulation . Another diagnosis malignancy require systemic treatment within 2 year randomization .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>castration resistant prostate cancer</keyword>
	<keyword>bone pain</keyword>
	<keyword>CRPC</keyword>
</DOC>